Skip to main content

vemurafenib

Generic: VEMURAFENIB·Brand: ZELBORAF, Zelboraf

vemurafenib: 7 clinical trials tracked.

vemurafenib evidence translation

What we can confirm

7 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about vemurafenib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (7)

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

NCT04943198Registry updated 2026-10-07·Phase 2
Active, not recruiting

Primary endpoint: event-free survival

InterventionalRandomizedopen25 enrolledStarted 2021-04Completion 2027-061 site · PolandAnna Raciborska

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

NCT04302025Registry updated 2026-02-09·Phase 2
Recruiting

Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)

Interventionalopen99 targetStarted 2020-11Completion 2030-0538 sites · United StatesGenentech, Inc.

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

NCT03768063Registry updated 2026-01-29·Phase 3
Active, not recruiting

Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)

Interventionalopen1,000 targetStarted 2019-02Completion 2028-0750 sites · Australia, Belgium, Brazil, Bulgaria…Hoffmann-La Roche

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

NCT03224767Registry updated 2026-10-07·Phase 2
Active, not recruiting

Primary endpoint: Response Rate

Interventionalopen24 enrolledStarted 2018-01Completion 2028-08106 sites · United StatesAlliance for Clinical Trials in Oncology

Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT02721459Registry updated 2026-03-02·Phase 1
Active, not recruiting

Primary endpoint: Maximum Tolerated Dose (MTD)

Interventionalopen26 targetStarted 2016-09Completion 2026-111 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

NCT02693535Registry updated 2026-09-22·Phase 2
Recruiting

Primary endpoint: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

Interventionalopen4,200 targetStarted 2016-03Completion 2028-1250 sites · United StatesAmerican Society of Clinical Oncology

A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma

NCT01659151Registry updated 2026-02-20·Phase 2
Completed

Primary endpoint: Percentage of Participants With Overall Response (OR)

Interventionalopen17 enrolledStarted 2012-08Completion 2025-081 site · United StatesH. Lee Moffitt Cancer Center and Research Institute